TY - JOUR
KW - organotypic
AU - David Pamies
AU - Anna Bal-Price
AU - Christophe Chesné
AU - Sandra Coecke
AU - Andras Dinnyes
AU - Chantra Eskes
AU - Regina Grillari
AU - Gerhard Gstraunthaler
AU - Thomas Hartung
AU - Paul Jennings
AU - Marcel Leist
AU - Ulrich Martin
AU - Robert Passier
AU - Jens C. Schwamborn
AU - Glyn N. Stacey
AU - Heidrun Ellinger-Ziegelbauer
AU - Mardas Daneshian
AB - A major reason for the current reproducibility crisis in the life sciences is the poor implementation of quality control measures and reporting standards. Improvement is needed, especially regarding increasingly complex in vitro methods. Good Cell Culture Practice (GCCP) was an effort from 1996 to 2005 to develop such minimum quality standards also applicable in academia. This paper summarizes recent key developments in in vitro cell culture and addresses the issues resulting for GCCP, e.g., the development of induced pluripotent stem cells (iPSCs) and gene-edited cells. It further deals with human stem-cell-derived models and bioengineering of organotypic cell cultures, including organoids, organ-on-chip and human-on-chip approaches. Commercial vendors and cell banks have made human primary cells more widely available over the last decade, increasing their use but also requiring specific guidance as to GCCP. The characterization of cell culture systems including high-content imaging and high-throughput measurement technologies increasingly combined with more complex cell and tissue cultures represent a further challenge for GCCP. The increasing use of gene editing techniques to generate and modify in vitro culture models also requires discussion of its impact on GCCP. International (often varying) legislations and market forces originating from the commercialization of cell and tissue products and technologies are further impacting on the need for the use of GCCP. This report summarizes the recommendations of the second of two workshops, held in Germany in December 2015, aiming to map the challenge and organize the process or developing a revised GCCP 2.0.
BT - Alternatives to Animal Experimentation
DA - 2018-07-09
DO - 10.14573/altex.1710081
IS - 3
LA - en
N2 - A major reason for the current reproducibility crisis in the life sciences is the poor implementation of quality control measures and reporting standards. Improvement is needed, especially regarding increasingly complex in vitro methods. Good Cell Culture Practice (GCCP) was an effort from 1996 to 2005 to develop such minimum quality standards also applicable in academia. This paper summarizes recent key developments in in vitro cell culture and addresses the issues resulting for GCCP, e.g., the development of induced pluripotent stem cells (iPSCs) and gene-edited cells. It further deals with human stem-cell-derived models and bioengineering of organotypic cell cultures, including organoids, organ-on-chip and human-on-chip approaches. Commercial vendors and cell banks have made human primary cells more widely available over the last decade, increasing their use but also requiring specific guidance as to GCCP. The characterization of cell culture systems including high-content imaging and high-throughput measurement technologies increasingly combined with more complex cell and tissue cultures represent a further challenge for GCCP. The increasing use of gene editing techniques to generate and modify in vitro culture models also requires discussion of its impact on GCCP. International (often varying) legislations and market forces originating from the commercialization of cell and tissue products and technologies are further impacting on the need for the use of GCCP. This report summarizes the recommendations of the second of two workshops, held in Germany in December 2015, aiming to map the challenge and organize the process or developing a revised GCCP 2.0.
PY - 2018
SP - 353
EP - 378
T2 - Alternatives to Animal Experimentation
TI - Advanced Good Cell Culture Practice for human primary, stem cell-derived and organoid models as well as microphysiological systems
UR - https://www.altex.org/index.php/altex/article/view/1000
VL - 35
Y2 - 2022-12-01
SN - 1868-8551
ER -